Integrated Wealth Concepts LLC Raises Holdings in Novartis AG (NYSE:NVS)

Integrated Wealth Concepts LLC increased its position in Novartis AG (NYSE:NVS) by 1.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 24,095 shares of the company’s stock after purchasing an additional 264 shares during the period. Integrated Wealth Concepts LLC’s holdings in Novartis were worth $2,345,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Bryn Mawr Capital Management LLC lifted its stake in Novartis by 0.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 12,884 shares of the company’s stock valued at $1,254,000 after buying an additional 100 shares during the last quarter. Rothschild Investment LLC boosted its stake in Novartis by 0.6% during the 4th quarter. Rothschild Investment LLC now owns 16,682 shares of the company’s stock worth $1,623,000 after purchasing an additional 101 shares during the period. Meridian Wealth Management LLC grew its position in Novartis by 2.6% during the 4th quarter. Meridian Wealth Management LLC now owns 4,161 shares of the company’s stock worth $405,000 after purchasing an additional 106 shares during the last quarter. Angeles Wealth Management LLC increased its stake in Novartis by 3.5% in the fourth quarter. Angeles Wealth Management LLC now owns 3,249 shares of the company’s stock valued at $316,000 after purchasing an additional 110 shares during the period. Finally, Heritage Family Offices LLP raised its holdings in shares of Novartis by 1.9% in the fourth quarter. Heritage Family Offices LLP now owns 6,107 shares of the company’s stock valued at $594,000 after buying an additional 112 shares during the last quarter. 13.12% of the stock is owned by institutional investors and hedge funds.

Novartis Price Performance

Shares of NYSE NVS opened at $112.23 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04. Novartis AG has a one year low of $96.06 and a one year high of $120.92. The firm has a market capitalization of $237.08 billion, a P/E ratio of 19.09, a PEG ratio of 1.70 and a beta of 0.56. The company’s fifty day moving average is $109.68 and its two-hundred day moving average is $106.10.

Novartis (NYSE:NVS) last released its quarterly earnings data on Friday, January 31st. The company reported $1.98 EPS for the quarter, topping analysts’ consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. Analysts forecast that Novartis AG will post 8.45 EPS for the current fiscal year.

Novartis Dividend Announcement

The company also recently disclosed a dividend, which was paid on Wednesday, March 12th. Investors of record on Wednesday, March 12th were paid a $3.8695 dividend. The ex-dividend date was Wednesday, March 12th. Novartis’s payout ratio is currently 44.05%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. UBS Group reissued a “neutral” rating on shares of Novartis in a report on Thursday, February 13th. BNP Paribas raised Novartis to a “strong-buy” rating in a report on Tuesday, April 15th. Deutsche Bank Aktiengesellschaft raised Novartis from a “hold” rating to a “buy” rating in a report on Tuesday, February 4th. Morgan Stanley started coverage on shares of Novartis in a research note on Wednesday, February 12th. They issued an “underweight” rating on the stock. Finally, Barclays reaffirmed an “underweight” rating on shares of Novartis in a report on Monday, February 3rd. Three research analysts have rated the stock with a sell rating, six have given a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.